Daewoong Pharmaceutical (Daewoong) is a South Korea-based pharmaceutical company, engaged in the manufacturing and selling of various kinds of drugs, chemicals and antibiotics. The company also operates in China, India, Thailand, Indonesia, Philippines, the US and Vietnam.
The company markets its products under the brand names of URSA, NABOTA, LUPHERE, EASYEF, EASYEF ointment, EPO, Caretropin, CuraVac, Meropenem and Iopromide.
Daewoong offers complex soft capsules used for the improvement of chronic hepatic disease, and systemic lassitude, body fatigue, dyspepsia and anorexia caused by liver function impairment under URSA brand.
The company;s NABOTA is used for temporary improvement of forehead lines associated with corrugator and/or procerus muscle activity in adult patients, and upper limb spasticity after stroke.
Daewoong, under the LUPHERE brand, offers Luphere Depot injections that are used for the treatment of prostatic cancer, endometriosis, premenopausal breast cancer, uterine leiomyomata (fibroids) and central precocious puberty. The company's EASYEF brand offers Easyef Liquid that is used for the treatment of diabetic foot ulcer.
The company offers EASYEF ointment, which is used to treat wound and topical adjuvant therapy of skin ulcer; EPO, which is used for the treatment of anemia of chronic renal failure patients such as secondary anemia and anemia required blood transfusion; Caretropine used as the growth hormone deficiency in adult; and CuraVac used for treatment of acute wounds, sub-acute wounds, chronic wounds, partial thickness burns, pressure ulcers, fistulae, and flaps and grafts.
Daewoong also offers Meropenem Injection, which is used for the treatment of sepsis, cellulitis, lymphadenitis, perianal abscess, osteomyelitis, arthritis, wound infection, pneumonia, peritonsillar abscess, bronchiectasis, secondary infection of chronic respiratory disease, lung abscess, pyothorax, pyelonephritis, complicated cystitis, cholecystitis, cholangitis, liver abscess, peritonitis, adnexitis, intrauterine infection, pelvic dead space infection, pelvic cellulitis, otitis media, paranasal sinusitis, bacterial meningitis, suspected infection in patients with leucopenia, and cystic fibrosis; and Iopromide, which is an active ingredient.
The company is also engaged in the research and development of new products in categories that include new chemical entity (NCE), incrementally modified drugs (IMD), active pharmaceutical ingredient (API), biologics, gene therapy, sustained release and fixed dose drug combinations (FDC).
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of Daewoong Pharmaceutical Co., Ltd. in terms of revenue, net income, and operating income.
-- Financials - Details about Daewoong Pharmaceutical Co., Ltd. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines Daewoong Pharmaceutical Co., Ltd.’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases Daewoong Pharmaceutical Co., Ltd.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of Daewoong Pharmaceutical Co., Ltd.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does Daewoong Pharmaceutical Co., Ltd. operate and what are key points about it?
-- What is the product / service portfolio of Daewoong Pharmaceutical Co., Ltd.?
-- How has Daewoong Pharmaceutical Co., Ltd. performed financially from the 2013?
-- How does Daewoong Pharmaceutical Co., Ltd. rank among its peers in terms of revenue and market share?
-- What are Daewoong Pharmaceutical Co., Ltd. strengths and weaknesses and what opportunities and threats does it face?
-- What are Daewoong Pharmaceutical Co., Ltd.’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of Daewoong Pharmaceutical Co., Ltd.? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us